BioCentury | Jan 4, 2020
Targets & Mechanisms

SIGLECs go from homing beacons to next-generation checkpoints

Propelled by growing understanding of their biology, and an expression pattern that goes well beyond T cells, SIGLEC proteins are rising as the next set of checkpoint targets to challenge PD-1. The sugar-binding proteins could...
BioCentury | Feb 8, 2019
Emerging Company Profile

Palleon: Sweeter checkpoints

With two platforms targeting glycan ligands and their receptors, and a third to match cancer patients to a therapy, Palleon Pharmaceuticals Inc. aims to treat cancer by removing the brakes on a class of checkpoints...
BC Innovations | Nov 30, 2018
Targets & Mechanisms

Adhesion targets emerge at ASH 2018

The next wave of targets in blood cancers and hematology will come from adhesion molecules, innate immune cells and regulators of gene expression, according to BioCentury’s analysis of emerging targets at ASH 2018. BioCentury’s analysis...
BioCentury | Feb 24, 2017
Product Development

Dendritic cell control

Denceptor Therapeutics Ltd. is developing a technology for inducing antigen-specific T cell responses that the company believes will be more efficacious than other dendritic cell-targeted approaches for cancer while avoiding the safety issues raised by...
BC Innovations | Dec 10, 2015
Distillery Therapeutics

Therapeutics: An undetermined target

Infectious disease INDICATION: Hepatitis C virus (HCV); HIV/AIDS; influenza virus Cell culture and mouse studies identified a modified lectin that could help treat HCV, HIV and influenza without the mitogenic side effects of natural lectins....
BC Innovations | Jul 30, 2015
Distillery Techniques

Techniques: Engineered CHO cell platform for producing biologics with human-like glycosylation patterns

Drug platforms TECHNOLOGY: Expression systems A panel of gene-edited CHO cells with altered glycosyltransferase gene expression could be used to produce biologics with homogeneous, human-like glycosylation patterns. The panel of CHO cells was generated by...
BC Innovations | May 7, 2015
Distillery Techniques

Techniques: Genetically encoded fragment-based discovery (GE-FBD)-based screening for glycopeptide inhibitors of lectins

Assays and screens TECHNOLOGY: High throughput screening University of Alberta...
BC Innovations | Mar 4, 2010
Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Bacterial infection ABO blood group (ABO) In vitro and mouse studies suggest that the lectins galectin-4 (LGALS4; GAL-4) and LGALS8 (GAL-8) could help kill...
BC Innovations | Jan 29, 2009
Targets & Mechanisms

Breaking the biofilm barrier

Bacterial biofilms compromise the use of implanted medical devices such as stents, catheters and ventilators because they can shed bacteria and cause infection elsewhere in a patient. These surface-attached bacterial communities are very difficult to...
BC Innovations | Oct 2, 2008
Targets & Mechanisms

Autoimmunity Gets Mincle and Dimed

Researchers at the RIKEN Research Center for Allergy and Immunology have identified MINCLE as a receptor that triggers neutrophil recruitment and secretion of proinflammatory cytokines in response to necrotic cells derived from injured tissue. 1...
Items per page:
1 - 10 of 33